Search

Your search keyword '"Van Praet, Serge"' showing total 12 results
Start Over Author "Van Praet, Serge"
12 results on '"Van Praet, Serge"'

1. Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and Favipiravir, Belgium, 2020

Author

Veliziotis, Ioannis, Roman, Alain, Martiny, Delphine, Schuldt, Gerlind, Claus, Marc, Dauby, Nicolas, Van den Wjngaert, Sigi, Martin, Charlotte, Nasreddine, Rakan, Perandones, Claudia, Mahieu, Romain, Swaan, Corien, Van Praet, Serge, Konopnicki, Deborah, Morales, Maria A., Malvy, Denis, Stevens, Etienne, Dechamps, Philippe, Vlieghe, Erika, Vandenberg, Olivier, Gunther, Stephan, and Gerard, Michele

Subjects
Management, International economic relations, Company business management, Vaccines, Lassa fever, Hemorrhagic fevers, Tazobactam, Levetiracetam, Ribavirin, Meropenem
Abstract

Argentine hemorrhagic fever (AHF) is a severe hemorrhagic fever caused by a New World arenavirus, Junin virus (JUNV), which was discovered in 1958 (1). The virus reservoir consists of rodents [...]

Published
2020
Full Text
View/download PDF

6. LC-MS analysis combined with PCA and SIMCA for a better detection of changes in N-glycosylation profiles of therapeutic glycoproteins

Author

GlycoBioTec 2017 (7-9 février 2017: Berlin), Planinc, Ana, Dejaegher, Bieke, Vander Heyden, Yvan, Viaene, Johan, Van Praet, Serge, Rappez, Florence, Van Antwerpen, Pierre, Delporte, Cédric, GlycoBioTec 2017 (7-9 février 2017: Berlin), Planinc, Ana, Dejaegher, Bieke, Vander Heyden, Yvan, Viaene, Johan, Van Praet, Serge, Rappez, Florence, Van Antwerpen, Pierre, and Delporte, Cédric

Abstract

info:eu-repo/semantics/nonPublished

Published
2017

7. LC-MS analysis combined with pca and simca for a better detection of changes in n-glycosylation profiles of therapeutic glycoproteins

Author

19th Forum of Pharmaceutical Sciences (17-18/10/2016: Bruxelles), Planinc, Ana, Dejaegher, Bieke, Vander Heyden, Yvan, Viaene, Johan, Van Praet, Serge, Rappez, Florence, Van Antwerpen, Pierre, Delporte, Cédric, 19th Forum of Pharmaceutical Sciences (17-18/10/2016: Bruxelles), Planinc, Ana, Dejaegher, Bieke, Vander Heyden, Yvan, Viaene, Johan, Van Praet, Serge, Rappez, Florence, Van Antwerpen, Pierre, and Delporte, Cédric

Abstract

info:eu-repo/semantics/nonPublished

Published
2016

10. Tolerability of favipiravir therapy in critically ill patients with COVID‐19: A report of four cases.

Author

Dauby, Nicolas, Van Praet, Serge, Vanhomwegen, Charlotte, Veliziotis, Ioannis, Konopnicki, Deborah, and Roman, Alain

Subjects
COVID-19, CRITICALLY ill, EBOLA virus disease
Abstract

Favipiravir (FVP) is an RNA polymerase inhibitor with broad antiviral activity.1 FVP is a prodrug that is ribosylated and phosphorylated intracellularly to form the active metabolite and has a short half-life (2-5.5 h) after oral administration.2 It is registered for the treatment of influenza infection in Japan and has been used in clinical trial for the treatment of Ebola virus infection (EBOV). All patients had increasing lymphocytes count during the course of FVP therapy, except the patient who deceased. FVP concentrations were found much lower than that of healthy subjects.9 Three of the four patients reported here received FVP late after symptoms onset (7-18 days), probably decreasing the possibility of an antiviral effect. [Extracted from the article]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results